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Translational Relevance (148 of 120-150 word limit):  
This phase II study of untreated patients with metastatic colorectal cancer compared efficacy and safety 
of tivozanib plus folinic acid, fluorouracil, and oxaliplatin (mFOLFOX6) vs. bevacizumab plus mFOLFOX6. 
The combination of tivozanib/mFOLFOX6 was tolerable and adverse events were comparable to both 
bevacizumab/mFOLFOX6 and previous tivozanib studies. Following a prespecified interim futility 
analysis, which demonstrated that the futility boundary for superiority of tivozanib over bevacizumab 
for progression-free survival (PFS) in the intent-to-treat population was crossed in this study, 
tivozanib/mFOLFOX6 resulted in PFS and overall response rates comparable to 
bevacizumab/mFOLFOX6. At the time of interim analysis, no significant association was found between 
biomarkers and PFS.  Post hoc final analyses demonstrated a statistical difference in PFS in patients with 
low neuropilin-1 (NRP-1), favoring the tivozanib combination arm, and no difference in patients with 
high NRP-1.  NRP-1 is a potential predictive biomarker for tivozanib activity and this biomarker 
association warrants further study.   
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Abstract  
Background: Tivozanib, a selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3, 
plus mFOLFOX6 in an advanced gastrointestinal cancer phase Ib study had encouraging antineoplastic 
activity and a tolerable safety profile. This randomized, open-label, phase II trial of tivozanib/mFOLFOX6 
vs. bevacizumab/mFOLFOX6 in patients with previously untreated metastatic colorectal cancer (mCRC) 
evaluated tivozanib activity vs. bevacizumab. 
Methods: Treatment-naïve patients received mFOLFOX6 every 2 weeks of each 28-day cycle plus either 
tivozanib orally 1.5 mg once daily for 21 days or bevacizumab intravenously 5 mg/kg every 2 weeks. 
Investigator-assessed progression-free survival (PFS) was the primary endpoint; some secondary 
endpoints included safety, overall survival, overall response rate (ORR), duration of response, time to 
treatment failure, and biomarker subgroup analyses. 
Results: A prespecified interim futility analysis demonstrated that the futility boundary for superiority of 
tivozanib/mFOLFOX6 over bevacizumab/mFOLFOX6 for PFS in the intent-to-treat population was 
crossed; median PFS was 9.4 vs. 10.7 months (HR=1.091; CI 0.693–1.718; P = 0.706). 
Tivozanib/mFOLFOX6 resulted in PFS and ORR comparable to bevacizumab/mFOLFOX6; interim analyses 
biomarker results revealed no significant PFS association.   Post hoc final analyses demonstrated a 
statistical difference in tivozanib-specific PFS in patients with low neuoropilin-1 (NRP-1), but not in 
patients with high NRP-1. Tivozanib/mFOLFOX6 was tolerable and adverse events were comparable to 
both bevacizumab/mFOLFOX6 and previous tivozanib studies. 
Conclusions: The efficacy of tivozanib/mFOLFOX6 was comparable to bevacizumab/mFOLFOX6 in 
patients with previously untreated mCRC; safety and tolerability profile of tivozanib/mFOLFOX6 was 
consistent with other tivozanib trials. NRP-1 is a potential predictive biomarker for tivozanib activity.   
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Introduction 
Colorectal cancer (CRC) is a prevalent and deadly cancer with an estimated 136,830 new cases and 
50,310 deaths in the United States in 2014 (1). Although 5-year survival rates remain low (9.8% to 17.7% 
across major racial/ethnic population and age groups), survival time for metastatic CRC (mCRC) has been 
improving (2). Additional therapeutic options including combination therapy and therapies with agents 
targeting the epidermal growth factor receptor (EGFR)- and vascular endothelial growth factor receptor 
(VEGFR)-signaling pathways have created a significant change in CRC therapy over the last decade, 
particularly for mCRC (3, 4). In particular, the addition of bevacizumab has become a standard in 
combination therapy for mCRC (5).  
Tivozanib is an oral VEGFR tyrosine kinase inhibitor (TKI) with selective inhibition of VEGFR-1, -2, and -3 
(6). It is more selective and potent than other VEGFR TKIs and was designed to optimize blockade of 
VEGFR while minimizing off-target toxicities (6–8). Tivozanib has a long half-life of approximately 4.5 
days, which allows once-daily dosing to maintain serum concentrations (7, 9).  
In a phase III trial in patients with renal cell carcinoma, tivozanib met its primary endpoint of 
progression-free survival (PFS), but failed to meet the overall survival (OS) secondary endpoint (10). One 
possibility is that crossover to sorafenib may have confounded the survival results (11). Tivozanib has 
also shown single-agent activity in patients with other solid tumors, including CRC (7, 12–14) and in 
combination with temsirolimus in patients with renal cell carcinoma (15), with paclitaxel in patients with 
metastatic breast cancer (16), and with everolimus in patients with metastatic colon cancer (17). 
Preclinical data demonstrated additive antitumor activity of tivozanib when combined with fluorouracil. 
A pharmacokinetic drug-drug interaction study showed that dosing of tivozanib with a CYP3A4 pathway 
inhibitor had no influence on tivozanib concentrations; however, a strong CYP3A4 inducer reduced 
tivozanib plasma concentration (9).  
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Tivozanib plus mFOLFOX6 (modified treatment regimen of: FOLinic acid, Fluorouracil, and OXaliplatin) 
was evaluated in a phase Ib study in patients with advanced gastrointestinal (GI) cancers, including 
mCRC (18). Results from this study showed that tivozanib can be safely combined at the recommended 
dose with mFOLFOX6 in patients with advanced GI tumors and also demonstrated encouraging 
antineoplastic activity with 30.8% of all patients achieving a partial response (18). A randomized, open-
label, phase II trial of tivozanib/mFOLFOX6 (Arm A) vs. bevacizumab/mFOLFOX6 (Arm B) in patients with 
previously untreated mCRC (BATON [Biomarker Assessment of Tivozanib in ONcology] -CRC; 
NCT01478594) was initiated to evaluate tivozanib activity vs. bevacizumab and to evaluate a predefined 
set of biomarkers for potential prediction of clinical response following tivozanib therapy. 
Materials and Methods 
Patients 
Male or female patients ≥18 years with histologically or cytologically confirmed mCRC, ≥1 measurable 
lesions by RECIST (Version1.1), no prior systemic chemotherapy, no fluorouracil-containing adjuvant 
therapy in the previous 6 months, and an Eastern Cooperative Oncology Group performance status 
(ECOG PS) ≤1 were included in the study. Patients were excluded if they had prior VEGF therapy 
(including bevacizumab) or a history of significant thromboembolic or vascular disorders within 6 
months of study entry. Patients with any of the following were also excluded: hematologic 
abnormalities; significant cardiovascular disease; history of serious GI toxicity, diarrhea, or stomatitis 
within 6 weeks of study entry; a GI condition with increased risk of perforation; history of abdominal 
fistula, GI perforation, or intraabdominal abscess within 4 weeks prior to study entry; and peripheral 
neuropathy ≥Grade 2. 
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All patients provided informed consent prior to performing any study-related procedures. Approval was 
obtained by the research ethics committee at each participating institution for the protocol, informed 
consent, patient information, and amendments. The study was conducted in accordance with the 
International Conference on Harmonization Good Clinical Practice with the ethical principles of the 
current version of Declaration of Helsinki.  
Study design 
This was a randomized, open-label, phase II trial designed to evaluate superiority of 
tivozanib/mFOLFOX6  over bevacizumab/mFOLFOX6 in patients with mCRC. Patients were randomized 
2:1 to tivozanib/mFOLFOX6 (Arm A) or bevacizumab/mFOLFOX6 (Arm B) and stratified by lactate 
dehydrogenase (LDH), origin of cancer, and number of metastatic sites. Patients received mFOLFOX6 
every 2 weeks on days 1 and 15 of each 28-day cycle with either tivozanib orally 1.5 mg once daily for 21 
days followed by 7 days off treatment (Arm A) or bevacizumab intravenously 5 mg/kg every 2 weeks on 
days 1 and 15 (Arm B).  
PFS by investigator-assessed radiological disease progression was the primary endpoint. Assessed 
secondary endpoints included safety, OS, overall response rate (ORR), duration of response (DOR), and 
time to treatment failure (TTF). PFS subgroup analyses and biomarker analyses of lactate dehydrogenase 
(LDH); VEGF A, C, D, and their ratios; CD68; myeloid-derived gene signature; and serum soluble 
cytokines were evaluated for any potential to predict response to tivozanib therapy. The trial initiated 
on December 20, 2011 and interim efficacy analyses were based on a September 13, 2013 data analysis 
cut off, which led to the termination of the study due to futility. Secondary endpoints of PFS by 
independent radiological review and health-related quality of life were not assessed due to early 
termination of the study. Disposition, safety, and biomarker analyses include data through trial follow-
up to February 28, 2014.  
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Safety and efficacy assessment 
Safety and tolerability was assessed by monitoring vital sign measurements, physical examinations, 12-
lead electrocardiograms (ECG), clinical laboratory tests (including hematology, urinalysis, serum 
chemistry, thyroid, coagulation, and pregnancy tests), cardiac biomarkers (troponin, creatine 
phosphokinase), ECOG PS, and adverse events (AEs) which were coded using NCI-CTCAE (v4.03). Dose 
reduction for toxicity was allowed for tivozanib and mFOLFOX6, but not for bevacizumab. Dose 
interruptions for all agents were allowed; however, interruption for longer than 2 weeks could result in 
treatment discontinuation as determined by the study investigator. Dose reductions of tivozanib and 
mFOLFOX6 could have occurred independently. Tivozanib was reduced to 1.0 mg/day for patients with 
Grade ≥3 AEs, and could not be re-escalated.  
Disease progression was assessed based on radiologic imaging (e.g., diagnostic computed tomography 
scans, magnetic resonance imaging scans) of the chest, abdomen, and pelvis every 8 weeks from the 
start of study medication for the first 18 months on study and then every 12 weeks until study end, 
disease progression, or death. PFS was defined as the time from the date of randomization until 
objective tumor progression (defined by RECIST v1.1) or death. Secondary efficacy variables were 
defined as follows: OS from the date of randomization until death from any cause, ORR was the 
proportion of patients with confirmed complete response (CR) or partial response (PR), DOR from the 
date of first documented CR or PR to the date of progression, and TTF from randomization to treatment 
discontinuation for any reason.  
Serum Biomarker Analysis 
A secondary objective to identify biomarkers that potentially could predict clinical response following 
tivozanib/mFOLFOX6 therapy or preferential response vs. bevacizumab/mFOLFOX6, included analysis of 
VEGF A, C, D, and their ratios; CD68; myeloid-derived gene signature; serum soluble cytokines; and 
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neuropilin-1 (NRP-1). Serum protein measurement for the biomarker analyses were measured using the 
Myriad Rules-Based Medicine system (Myriad RBM, Austin, TX).  These multiplexed assays are based on 
the capture-sandwich format using capture antibodies attached to fluorescently encoded microspheres. 
After capture of antigen from a biological sample, such as serum, the antigen is then detected using 
specific detection antibodies coupled to a fluorescent probe. Biomarker measurement was categorized 
as below or above the median. 
Statistical analysis 
A total of 166 PFS events were planned for the study to provide 80% power at a one-sided type I error of 
0.2 to detect a statistically significant treatment effect of tivozanib/mFOLFOX6 over 
bevacizumab/mFOLFOX6 using a log-rank test assuming a median PFS for bevacizumab/mFOLFOX6 of 
9.4 months (19) and a 3-month improvement for tivozanib/mFOLFOX6. An interim futility analysis for 
superiority was planned for when approximately 83 PFS events (50% of the total) were observed with a 
futility boundary of hazard ratio (HR)>1.0581. The actual number of PFS events (95, 57.2% of the 
required 166 events) changed the futility stopping boundary to an HR>1.004 according to the 
prespecified Lans-DeMets beta spending function for O’Brien-Fleming boundary. The full analysis set 
was defined as all randomized patients and was used for primary analyses of efficacy as well as 
demographic and baseline characteristics. The safety analysis set consisted of all patients who received 
≥1 dose of study drug. The distribution of the primary endpoint, PFS, was estimated for each treatment 
arm using the Kaplan-Meier method and compared between arms using a stratified log-rank test. A Cox 
proportional hazard model along with the 95% confidence interval (CI) was used to assess PFS, OS, TTF, 
and DOR as well as the association between potential serum biomarkers and PFS with treatment arms as 
the covariate. ORR and corresponding CIs were calculated for each treatment arm and compared 
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between 2 arms using a stratified Cochran-Mantel-Haenszel test. All data processing, summarization, 
and analyses were performed using SAS® Version 9.2 or above in a UNIX environment. 
 
Results 
Patients 
The study was conducted at 73 sites in 12 countries including Australia (8), Austria (3), Belgium (4), 
Canada (5), Czech Republic (2), Finland (2), Hungary (4), Italy (4), the Netherlands (1), Spain (6), United 
Kingdom (7), and the United States (27). From December 2, 2011 through April 28, 2013, 265 subjects 
were randomized, 177 to tivozanib/mFOLFOX6 (Arm A) and 88 to bevacizumab/mFOLFOX6 (Arm B) 
(Supplementary Figure S1). In Arm A, all 177 patients were included in both the full and safety analysis 
set and 158 patients (89%) discontinued study treatment (61 patients [38.6%] primarily because of an 
AE and 55 [34.8%] because of progressive disease). In Arm B, 88 patients were included in the full 
analysis set, but one patient did not receive study drug and was not included in the safety analysis set;  
81 patients [92%] discontinued study treatment (28 patients [34.6%] primarily due to an AE and 34 
[42.0%] due to progressive disease). Median dose intensity for the combination dose was similar 
between the 2 arms at 83% in Arm A and 86% in Arm B. Likewise, median duration of treatment was 
similar (168.0 days Arm A and 162.0 days Arm B). Patient baseline demographic and disease 
characteristics are presented in Table 1 and are generally balanced between the two treatment groups 
except that Arm A had a higher proportion of patients with an ECOG PS of 1 (46.3 vs. 34.1%). 
Safety 
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The overall safety profile was comparable between treatment arms. In both treatment arms, the most 
common all grade treatment emergent adverse event (TEAE) was diarrhea (58.2% Arm A and 57.5% Arm 
B) and the most common Grade 3/4 TEAE was neutropenia (39.5% Arm A and 24.1% Arm B) (Table 2). 
The most common treatment-related AE in both arms was hypertension (39.5% Arm A and 25.3% Arm 
B). An AE led to permanent discontinuation in 41.2% of patients in Arm A and 34.5% of patients in Arm B 
(although not necessarily the primary reason for discontinuation). Pulmonary embolism and deep vein 
thrombosis were the most common AEs leading to discontinuation for Arm A and Arm B, respectively. 
Serious AEs (SAEs) were reported for 46.3% of patients in Arm A compared with 48.3% in Arm B. The 
two most common SAEs in Arm A were diarrhea (4.0% Arm A, 5.7% Arm B) and pulmonary embolism 
(4.0% Arm A, 0% Arm B), and in Arm B were pyrexia (2.3% Arm A, 8.0% Arm B) and diarrhea (as reported 
above). Serious treatment-related AEs were reported in 21.5% of patients for tivozanib (most common 
being pulmonary embolism at 2.8%) and in 17.2% patients for bevacizumab (most commonly abdominal 
pain at 3.4%). 
A total of 9 patients died while on treatment or within 30 days of last dose. There were 7 deaths (4.0%) 
in Arm A with 3 patients having at least one fatal AE considered to be probably related to tivozanib 
(pulmonary hemorrhage, gastrointestinal hemorrhage, and duodenal neoplasm) or possibly related 
(asthenia). There were 2 deaths (2.3%) in Arm B patients, both of which were due to AEs probably 
related to bevacizumab (hepatic hemorrhage and large intestine perforation). 
Efficacy 
A prespecified interim analysis included 95 PFS events and met the prespecified futility criteria. Median 
PFS (Arm A vs. Arm B) was 9.4 vs. 10.7 months (HR = 1.091; CI 0.693–1.718; P = 0.706) (Table 3, Figure 
1). Complete responses were achieved for 4 patients (2.3%) in Arm A and 1 patient (1.1%) in Arm B and 
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ORR (Arm A vs. Arm B) was 45.2% vs. 43.2% (P = 0.718) (Table 3).  In addition, Arm A vs. Arm B median 
DOR was 7.4 vs. 9.3 months (HR = 1.389; CI 0.604–3.194; P = 0.437), median TTF was 5.5 vs. 5.4 months 
(HR = 1.006; CI 0.764–1.358; P = 0.967), and median OS was not reached for either arm. Because the 
data from the prespecified interim analysis demonstrated futility for superiority, the study was 
discontinued.  Post hoc analysis of final data of 91 and 50 events for Arm A and Arm B, respectively 
showed a median PFS  of 9.8 vs 9.5 months (HR = 0.908; CI 0.624–1.301; P = 0.598) and an ORR of 46.9% 
in Arm A vs. 43.2% in Arm B. Subgroup analysis did not show significant differences in PFS (Figure 2A). A 
trend of benefit was observed in the predefined LDH high (>1.5 upper limit of normal [ULN]) subgroup. 
A secondary objective of the study was to evaluate the value of potential predefined biomarkers for 
preferential response of tivozanib/mFOLFOX6 vs. bevacizumab/mFOLFOX6. None of the biomarker 
analyses showed significant differences at the time of the interim analysis.  Post hoc exploratory 
biomarker analyses were conducted on 164 (62%) patient samples based on final efficacy data collected 
through February 28, 2014. The PFS HR along with the 95% confidence interval is presented for each 
biomarker subgroup (Figure 2B).    
NRP-1, the biomarker found to be most associated with increased PFS, was analyzed further to 
determine if it had potential prognostic value for tivozanib and bevacizumab and potential predictive 
value for tivozanib over bevacizumab in the low NRP-1 selected population. In both treatment arms, 
there was an increase in PFS in patients with NRP-1 below the median (NRP-1 low) (Figure 3A and 3B), 
consistent with other studies (20, 21) and suggesting a potential prognostic biomarker. Additionally, 
there is a statistically significant difference in PFS in patients with low NRP-1 in favor of Arm A with no 
difference in high NRP-1 (above median NRP-1), suggesting that NRP-1 could be a potential predictive 
marker as well as a prognostic marker (Figure 3C and D); for NRP-1 low patients, PFS was 17.9 months in 
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the tivozanib-treated patients and 11.2 months in the bevacizumab-treated patients (HR =0.38; 
unstratified P value 0.0075).       
 
Discussion 
In this randomized, open-label, phase II trial of tivozanib/mFOLFOX6 vs. bevacizumab/mFOLFOX6 in 
patients with previously untreated mCRC, a prespecified interim futility analysis demonstrated that the 
futility boundary for superiority of tivozanib over bevacizumab for PFS in the intent-to-treat (ITT) 
population  was crossed, resulting in discontinuation of the study. At this interim analysis, the 
combination of tivozanib/mFOLFOX6 resulted in PFS, ORR, TTF, and DOR comparable to that of 
bevacizumab/mFOLFOX6. Also at this interim analysis, subgroup and biomarker analyses revealed no 
significant association with PFS, although LDH-1 and NRP-1 showed a trend of PFS benefit.   At the post 
hoc final analysis, NRP-1 low (below the median) did demonstrate a statistical difference in PFS favoring 
the tivozanib/mFOLFOX6 arm. The safety profile of the combination of tivozanib/mFOLFOX6 was 
consistent with the safety profile reported to date in other tivozanib studies of patients with advanced 
disease (7, 10, 15, 16, 18) and comparable to that of bevacizumab/mFOLFOX6. 
Bevacizumab plus chemotherapy has been shown to improve OS compared with chemotherapy alone in 
patients with mCRC (3, 4). Specifically, bevacizumab added survival benefits when added to treatment 
with various FOLFOX therapies (19, 22), although the benefits may be specific to PFS according to a 
recent meta-analysis (23). Bevacizumab/mFOLFOX6 is considered to be a standard treatment for mCRC, 
and the combination has been used as a comparison arm in several first-line mCRC clinical trials, 
including those involving panitumumab (24), cediranib (25), axitinib (26), cetuximab (19, 27), and XELOX 
(capecitabine and oxaliplatin)/SOX (oxaliplatin and S-1) (28, 29). In the current study at the interim 
futility analysis, the efficacy of tivozanib/mFOLFOX6 was comparable to that of bevacizumab/mFOLFOX6 
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with a PFS of 9.4 vs. 10.7 months (HR = 1.091; CI 0.693–1.718; P = 0.706) and ORR 45.2% vs. 43.2%; the 
post hoc final analysis of PFS was 9.8 vs. 9.5 months (HR = 0.908; CI 0.624–1.301; P = 0.598). 
Furthermore, the bevacizumab/mFOLFOX6 results were comparable to those previously observed in 
recent comparison studies in similar patient populations treated with first-line therapy, which reported 
a bevacizumab/FOLFOX6 PFS range of 10.1 to 15.9 months and an ORR range of 47.3% to 63% (21, 24– 
26, 28, 29).  
In the current study, none of the subgroup analyses revealed significant differences in PFS. However, a 
trend of PFS benefit was observed in the predefined LDH high (≥1.5 ULN) subgroup (HR = 0.67; CI 0.37–
1.19). LDH levels were investigated in this study based on previous studies demonstrating increased 
efficacy associated with high LDH in patients treated with vatalanib combined with FOLFOX4 (30, 31). 
High LDH levels have been associated with survival in patients with mCRC treated with bevacizumab. Yin 
and colleagues (2014) reported an improvement in PFS in patients treated with first-line bevacizumab 
associated with high serum LDH levels (32). Similarly, high LDH level was designated a factor for 
improved prognosis in patients treated with first-line bevacizumab (33) and in patients treated with 
FOLFIRI (irinotecan, fluorouracil, and folinic acid) or XELOX plus anti-VEGF therapy (34). Additionally, a 
high level of LDH was reported to be one of only 5 parameters associated with survival in ≥3 studies 
included in a systematic review of 29 bevacizumab studies (35). However, the association is not 
definitive. High LDH levels were associated with worse prognosis in the HORIZON I study (36) and in a 
large single-center analysis (37).  
PFS was not significantly changed in this study in the ITT population. It is possible that the high 
percentage of AEs leading to permanent discontinuation seen in the current study (41.2% Arm A and 
34.5% Arm B), which led to a median duration of treatment of 168 and 162 days, may have confounded 
the estimate of median PFS in both study arms. Previous studies with bevacizumab suggest high 
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discontinuation observed for reasons other than disease progression could have potentially affected 
survival endpoints, but not the treatment response (19, 38).  
In light of the move toward personalized treatments in mCRC, potential biomarkers are an important 
aspect of treatment investigation. RAS is the only established predictive biomarker in the treatment of 
mCRC (39). To date, although LDH and NRP-1 levels have been shown to be prognostic for 
antiangiogenesis therapy (32–35, 40), no predictive factor for anti-VEGF therapy has been identified 
(39). In the current study, the biomarkers that were investigated were largely based on tivozanib 
mechanism (VEGF-C, VEGF-A, sVEGFR2, and sVEGFR3) and antiangiogenic properties (interleukin 8). 
These biomarkers were investigated to find a potential predictor of clinical response following tivozanib 
therapy based on the premise that reduced ligand and their respective soluble receptor levels have been 
associated with longer PFS and ORR in previous sunitinib studies (41, 42).  RNA expression levels from 
patient archival formaldehyde fixed-paraffin embedded tumor samples and circulating serum protein 
levels were evaluated for VEGF-A, -C, -D and placental growth factor ligand levels as well as VEGF C/ 
VEGF A ratios. Additionally, circulating NRP-1 protein, which was reported to be highly correlated with 
PFS following treatment of renal cancer with tivozanib (40), was also evaluated in serum.  NRP-1 is a 
VEGFR-2 coreceptor and is involved in the regulation of VEGFR-2–mediated angiogenesis (43, 44). 
Although there was no statistical difference in the ITT analysis, the results presented here following the 
preplanned, post hoc biomarker efficacy analysis suggest that serum NRP-1 could identify a subset of 
patients who would benefit from treatment with tivozanib rather than bevacizumab in combination with 
chemotherapy. A  PFS HR of 0.38 for tivozanib compared with bevacizumab, both in combination with 
FOLFOX chemotherapy, was observed in patients with serum NRP-1 levels below the median for the 
patients included in the trial analysis.  A second detection antibody was subsequently evaluated 
resulting in qualitatively similar data.  Additional efforts are underway to screen antibodies suitable for 
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use as a companion diagnostic to further validate serum NRP-1 as a biomarker to identify those patients 
most likely to respond to tivozanib. 
This study has demonstrated that the tivozanib/FOLFOX6 combination treatment is tolerable in patients 
with mCRC. The AEs noted with the combination were comparable to those observed in previous studies 
with tivozanib in combination with other therapies (15– 17) and with tivozanib alone (7, 10). The safety 
of the tivozanib/FOLFOX6 combination was also comparable to the bevacizumab/FOLFOX6 combination. 
The most common treatment-related AE in both study arms was hypertension, which is characteristic of 
VEGF-targeted therapy (45).  
In conclusion, although data from the prespecified interim analysis demonstrated futility for superiority 
and resulted in discontinuation of this study, the efficacy of tivozanib/mFOLFOX6 was comparable to 
that of bevacizumab/mFOLFOX6 in patients with previously untreated mCRC. Moreover, the safety 
profile of tivozanib/mFOLFOX6 was consistent with that seen with other trials with tivozanib in similar 
patient populations. Notably, low NRP-1 emerged as a potential predictive biomarker for tivozanib 
activity which may warrant further study.  
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Table 1. Baseline Patient Characteristics 
 Tivozanib 
+mFOLFOX6 
(n = 177) 
Bevacizumab 
+mFOLFOX6 
(n = 88) 
Total 
(n = 265) 
Sex, n (%) 
Male 
Female 
 
118 (66.7) 
59 (33.3) 
 
55 (62.5) 
33 (37.5) 
 
173 (65.3) 
92 (34.7) 
Age, mean (SD)  61.9 (9.6) 62.6 (11.2) 62.2 (10.1) 
Age group, n (%) 
<65 years 
≥65 years 
 
101 (57.1) 
76 (42.9) 
 
48 (54.5) 
40 (45.5) 
 
149 (56.2) 
116 (43.8) 
Race, n (%) 
White 
Black 
Asian  
 
169 (95.5) 
2 (1.1) 
3 (1.7) 
 
85 (96.6) 
0 
2 (2.3) 
 
254 (95.8) 
2 (0.8) 
5 (1.9) 
ECOG performance score, n (%)  
0 
1 
 
95 (53.7) 
82 (46.3) 
 
58 (65.9) 
30 (34.1) 
 
153 (57.7) 
112 (42.3) 
LDH status, n (%) 
<1.5 x ULN 
≥1.5 x ULN 
 
127 (71.8) 
50 (28.2) 
 
64 (72.7) 
24 (27.3) 
 
191 (72.1) 
74 (27.9) 
Origin of cancer, n (%) 
Rectal 
Colon 
 
53 (29.9) 
124 (70.1) 
 
24 (27.3) 
64 (72.7) 
 
77 (29.1) 
188 (70.9) 
No. of metastatic sites/organs, n (%)  
1 
2 
3 
≥4  
 
56 (31.6) 
80 (45.2) 
29 (16.4) 
12 (6.8) 
 
30 (34.1) 
34 (38.6) 
21 (23.9) 
3 (3.4) 
 
86 (32.5) 
114 (43.0) 
50 (18.9) 
15 (5.7) 
KRAS mutation status, n (%) 
Wild-type 
Mutant 
Unknown 
 
33 (18.6) 
23 (13.0) 
121 (68.4) 
 
21 (23.9) 
16 (18.2) 
51 (58.0) 
 
54 (20.4) 
39 (14.7) 
172 (64.9) 
Time since initial diagnosis in months, mean (SD) 9.4 (20.5) 10.9 (21.1) 9.9 (20.6) 
No. metastatic sites at screening, mean (SD) 2.0 (1.02) 2.0 (0.85) 2.0 (0.97) 
Prior therapy, n (%) 
Adjuvant therapy 
Surgery or procedure 
Radiation 
 
29 (16.4) 
115 (56.0) 
18 (10.2) 
 
19 (21.6) 
54 (61.4) 
13 (14.8) 
 
48 (18.1) 
169 (63.8) 
31 (11.7) 
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ECOG, Eastern Cooperative Oncology Group; KRAS, Kirsten rat sarcoma; LDH, lactate dehydrogenase; SD, 
standard deviation; ULN, upper limit of normal 
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Table 2. All-Grade Treatment Emergent AEs ≥20% Patients in Either Treatment and Grade 3/4 
Treatment Emergent AEs 
 Tivozanib/mFOLFOX6 (Arm A) 
(n = 177) 
Bevacizumab/mFOLFOX6 (Arm B) 
(n = 88) 
Adverse Event, n (%)  All-Grade Grade 3/4 All-Grade Grade 3/4 
Diarrhea  103 (58.2) 19 (10.7) 50 (57.5) 9 (10.3) 
Nausea 99 (55.9) 5 (2.8) 47 (54.0) 2 (2.3) 
Fatigue  97 (54.8) 20 (11.3) 46 (52.9) 8 (9.2) 
Neutropenia  95 (53.7) 70 (39.5) 37 (42.5) 21 (24.1) 
Hypertension  79 (44.6) 29 (16.4) 25 (28.7) 9 (10.3) 
Peripheral neuropathy  75 (42.4) 18 (10.2) 34 (39.1) 11 (12.6) 
Decreased appetite  64 (36.2) 2 (1.1) 25 (28.7) 2 (2.3) 
Vomiting  60 (33.9) 10 (5.6) 24 (27.6) 1 (1.1) 
Thrombocytopenia  54 (30.5) 10 (5.6) 13 (14.9) 2 (2.3) 
Constipation  50 (28.2) 1 (0.6) 32 (36.8) 1 (1.1) 
Paresthesia  46 (26.0) 2 (1.1) 20 (23.0) 3 (3.4) 
Abdominal pain  45 (25.4) 7 (4.0) 17 (19.5) 5 (5.7) 
Dysphonia  42 (23.7) 1 (0.6) 13 (14.9) 0 
Mucosal inflammation  40 (22.6) 5 (2.8) 29 (33.3) 6 (6.9) 
Asthenia  39 (22.0) 5 (2.8) 17 (19.5) 1 (1.1) 
Stomatitis  37 (20.9) 3 (1.7) 14 (16.1) 2 (2.3) 
Epistaxis  34 (19.2) 0 25 (28.7) 0 
Dysgeusia  26 (14.7) 0 18 (20.7) 0 
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Table 3. Summary of Efficacy and Response 
Efficacy Endpoint  
Tivozanib/mFOLFOX6 
(Arm A) 
(n = 177) 
Bevacizumab/mFOLFOX6 
(Arm B) 
(n = 88) 
HR (95% 
CI) 
P 
Value 
Progression-free survival  (Investigator-assessed)  
Disease progression, 
n (%)  
58 (32.8) 26 (29.5) 
1.091 
(0.693, 
1.718) 
0.706 Death, n (%)  8 (4.5) 3 (3.4) 
Median, months 
(95% CI)  
9.4 (8.5, 10.1) 10.7 (7.5, 12.8) 
Overall survival    
  
Event, n (%)  26 (14.7) 12 (13.6) 1.116 
(0.561, 
2.218) 
0.754 Median, months 
(95% CI)  
NA (NA, NA) NA (12.8, NA) 
Duration of response    
  
Event, n (%)  28 (35.0) 10 (26.3) 1.389 
(0.604, 
3.194) 
0.437 Median, months 
(95% CI)  
7.4 (5.6, 11.3) 9.3 (7.3, 10.7) 
Time to treatment 
failure  
  
  
Event, n (%)  138 (78.0) 65 (73.9) 1.006 
(0.746, 
1.358) 
0.967 Median, months 
(95% CI)  
5.5 (4.9, 7.1) 5.4 (3.7, 6.7) 
Best overall response, n 
(%)  
  
  
Complete response  4 (2.3)  1 (1.1)  NA 
 
Partial response  76 (42.9)  37 (42.0)  NA 
 
Stable disease  80 (45.2)  38 (43.2)  NA 
 
Progressive disease   6 (3.4)  5 (5.7)  NA 
 
Not evaluable  11 (6.2)  7 (8.0)  NA 
 
Confirmed overall 
response rate  
80 (45.2)  38 (43.2)  NA 
0.718 
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Figure 1: Survival probability of PFS   
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Figure 2: Subgroup Analyses (A) and biomarker Analysis (B) of PFSa.  
 
(A) 
 
(B) 
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aSerum values indicate protein levels in circulation and the categories for tumor biomarkers indicate 
RNA expression. 
ECOG, Eastern Cooperative Oncology Group;IL-8, interleukin-8; LDH, lactate dehydrogenase; PFS, 
progression-free survival; PIGF, placental growth factor; sVEGFR, serum vascular endothelial growth 
factor receptor; VEGF, vascular endothelial growth factor. 
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Figure 3: Low vs. high NRP-1 PFS (A, tivozanib; B, bevacizumab) and tivozanib vs. bevacizumab PFS in 
patients with low NRP-1 (C) or high NRP-1 (D) 
  
         
CI, confidence interval; HR, hazard ratio, NRP, neuropilin, PFS, progression-free survival.   
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Supplemental Figure 1. Patient Disposition 
 
aThe “recovery” category consisted of patients who had tumor shrinkage sufficient to discontinue 
treatment in order to have resection/curative surgery. 
b“Other” included physician decision, complete treatment response, patient wanted to pursue other 
treatment options, etc. 
AE, adverse event; FAS, full analysis set; PD, progressive disease; SAS, safety analysis set.  
 
 
